Navigation Links
CTRC-AACR San Antonio Breast Cancer Symposium

The CTRC-AACR San Antonio Breast Cancer Symposium features the latest findings in laboratory, translational and clinical breast cancer research. This year's meeting focuses on new and promising therapeutic approaches, as well as strides being made in diagnosing and preventing breast cancer.

To help you take the best advantage of the symposium's scientific abstracts and related activities, we encourage you to visit to view the new press policies developed in partnership with the American Association for Cancer Research (AACR).

The 2008 San Antonio Breast Cancer Symposium (SABCS) will be the first Symposium presented by the CTRC (Cancer Therapy & Research Center) at the University of Texas Health Science Center at San Antonio, AACR and the Baylor College of Medicine. More than 1,000 abstracts will be presented at the symposium, complementing an outstanding program of scientific and educational events.


  • Practice-changing data on the role of zolendric acid in late-stage breast cancer
  • How changes in breast density can predict outcome with tamoxifen
  • Why rest is as important as physical activity in breast cancer prevention
  • Recurrence rates among patients with small HER2-positive tumors
  • Evaluation of letrozole as adjuvant endocrine therapy
  • Phase III trials of new, paradigm-shifting clinical agents like topoisomerase

December 10-14, 2008

Henry B. Gonzales Convention Center
San Antonio, TX

CTRC-AACR Press Room:
Location: Room 217 A/B, Convention Center
Hours: Wed. 12:00 p.m. to 7:00 p.m.
Thurs. to Sat. 8:00 a.m. 7 p.m.
Sun. 8:00 a.m. 12:00 p.m.


Hotel Accommodations:
Housing registration is open. Please visit:

Contact/Press Registration:
Jill Byrd
Ph: (210) 450-5550
Fax: (210) 450-1686


Contact: Jill Byrd
American Association for Cancer Research

Related biology news :

1. 31st Annual San Antonio Breast Cancer Symposium
2. UC Davis researchers discover a key to aggressive breast cancer
3. Study links nicotine with breast cancer growth and spread
4. SNM releases new fact sheet on breast cancer and molecular imaging
5. Study looks at psychological impact of gene test for breast cancer
6. Second lumpectomy for breast cancer reduces survival rates
7. Breast cancer cells recycle to escape death by hormonal therapy
8. The dietary supplement genistein can undermine breast cancer treatment
9. Breast cancer treatment resistance linked to signaling pathway
10. Expanding cell girth indicates seriousness of breast cancer
11. Stem cells may solve mystery of early pregnancy breast cancer protection
Post Your Comments:
(Date:10/6/2015)... 2015 Track Group, Inc. (OTCQX: TRCK), a ... signed a contract with the Virginia Department of Corrections ... of sentences under the Department,s oversight. Derek ... contract with the Virginia DOC will expand our footprint ... our position as a trusted leader in offender electronic ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/30/2015)... 2015  The U.S. Court of Appeals for the ... in favor of Crossmatch ™, affirming the International ... Suprema and its U.S. partner Mentalix violated Section 337 ... that declares it unlawful to engage in "unfair practices" ... Crossmatch,s patents, the 5,900,993 patent and the 7,203,344 patent. ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... ... October 13, 2015 , ... The ... school age children in the areas of Science, Technology, Engineering and Mathematics. The ... national economy, and the program aims to increase the number of students who ...
(Date:10/12/2015)... South Carolina (PRWEB) , ... October 12, 2015 , ... ... to announce the release of the CSM-C 600 compact clean steam generator . ... saturated steam that meets the requirements of HTM2031, HTM2010, and EN285 standards. The ...
(Date:10/12/2015)... , Oct. 12, 2015  Rebiotix Inc. today ... has designated its lead Microbiota Restoration Therapy (MRT) ... of recurrent Clostridium difficile (C diff) ... that causes 29,000 deaths in the U.S. annually. ... company that was founded to revolutionize the treatment ...
(Date:10/12/2015)... , Oct. 12, 2015 /PRNewswire/ - Aeterna Zentaris ... biopharmaceutical company engaged in developing and commercializing novel treatments ... departure of Dennis Turpin , the Company,s former ... to close its Quebec City ... President and Chief Executive Officer of the Company commented, ...
Breaking Biology Technology: